Large-scale analysis reveals the specific clinical and immune features of CD155 in glioma
Large-scale analysis reveals the specific clinical and immune features of CD155 in glioma
复制标题
大规模分析揭示了胶质瘤中CD155的特异性临床和免疫特征
DOI：
10.18632/aging.102131
复制
发表时间：
2019-08-15
期刊：
影响因子：
5.2
通讯作者：
Liu, Zhixiong
中科院分区：
文献类型：
--
作者：
Liu, Fangkun;Huang, Jing;Liu, Zhixiong
近年来的研究表明，CD155在抗肿瘤免疫应答中发挥着重要作用。然而，它在神经胶质瘤中的作用尚不清楚。在这里，我们确定CD155是胶质瘤中一个有希望的免疫靶点。CD155在胶质母细胞瘤中显著高表达，而在正常脑组织中不表达。随后基于Rembrandt和TCGA数据集中1173例胶质瘤患者的遗传和临床数据分析表明，免疫应答的CD155相关基因主要与CD155表达呈正相关。CD155的表达与免疫相关宏细胞STAT1、HCK、LCK和MHC I呈正相关，与IgG呈负相关。CD155表达与浸润性免疫细胞生物标志物基因表达呈正相关，提示高表达的胶质瘤中浸润性免疫细胞比低表达的胶质瘤多。Pearson相关分析显示，CD155与CD96、CD226、Nectin4、PD-L1、B7-H2、NR2F6和GITR相关，提示这些检查点蛋白具有潜在的协同作用。这些发现暗示CD155是一个有希望的免疫治疗靶点，结合现有的免疫检查点阻断疗法治疗胶质瘤。
Recent studies demonstrated that CD155 plays an important role in anti-tumor immune responses. However, its role in glioma remains unclear. Here, we identify CD155 as a promising immune target in glioma. CD155 expression was significantly highly expressed in glioblastoma but not in normal brain tissue. Subsequent analysis based on genetic and clinical data from 1173 glioma patients in Rembrandt and TCGA dataset suggested that CD155 related genes of immune response were mainly positively correlated with CD155 expression. CD155 expression was positively correlated with immune-related metagenes STAT1, HCK, LCK, and MHC I but negatively associated with IgG. CD155 expression was positively correlated with biomarker gene expression of infiltrating immune cells, suggested that high CD155 expression in gliomas tend to have more infiltrating immune cells compared with gliomas with low CD155 expression. Pearson correlation analysis showed that CD155 is associated with CD96, CD226, Nectin4, PD-L1, B7-H2, NR2F6 and GITR, implying the potential synergistic effects of these checkpoint proteins. These findings implied that CD155 is a promising immunotherapy target, combined with existing immune checkpoint blockade therapies for glioma.